ReviewInternational journal of endocrinology2017
Antithyroid Drug Therapy for Graves' Disease and Implications for Recurrence.
Review in International journal of endocrinology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 49 citations in OpenAlex.
- Lithium carbonate as add-on therapy to radioiodine in the treatment on hyperthyroidism: a systematic review and meta-analysis.BMC endocrine disorders · 2021Pooled it
- Lithium carbonate bridging and outcomes of radioiodine therapy in severe Graves' disease: a retrospective cohort study.Frontiers in endocrinology · 2026Article
- Unusual Management of a Rare Case of Methimazole-Resistant Graves Disease.JCEM case reports · 2025Article
- From routine to rescue: Thyroidectomy for life-threatening thyrotoxicosis.World journal of surgery · 2024Article
- Efficacy of Anti-Thyroid Medications in Patients with Graves' Disease.BMC endocrine disorders · 2024Article
- Down Syndrome and Autoimmune Disease.Clinical reviews in allergy & immunology · 2024Review
- Efficacy of Radioiodine Therapy in Patients With Primary Hyperthyroidism: An Institutional Review From Pakistan.Cureus · 2022Article
- Graves' disease in a patient with Down syndrome: a shift from hyperthyroidism to hypothyroidism.BMJ case reports · 2021Article
- Practice patterns and outcomes in the management of Thai patients with Graves' disease.Thyroid research · 2021Article
- Prediction of Genetic Factors of Hyperthyroidism Based on Gene Interaction Network.Frontiers in cell and developmental biology · 2021Article
- Recurrence of Graves' Disease: What Genetics of HLA andFrontiers in endocrinology · 2021Article
- Challenges and perspectives of selenium supplementation in Graves' disease and orbitopathy.Hormones (Athens, Greece) · 2020Review
- The clinical phenotype of Graves' disease occurring as an isolated condition or in association with other autoimmune diseases.Journal of endocrinological investigation · 2020Observational
- Changes in Thyroid Peroxidase and Thyroglobulin Antibodies Might Be Associated with Graves' Disease Relapse after Antithyroid Drug Therapy.Endocrinology and metabolism (Seoul, Korea) · 2019Article
- Transoral Vestibular Thyroidectomy: Current State of Affairs and Considerations for the Future.The Journal of clinical endocrinology and metabolism · 2019Article
- Predictive Value of Gene Polymorphisms on Recurrence after the Withdrawal of Antithyroid Drugs in Patients with Graves' Disease.Frontiers in endocrinology · 2017Review
- HIGH THYROPEROXIDASE ANTIBODY TITERS MAY PREDICT RESPONSE TO ANTITHYROID DRUG TREATMENT IN GRAVES DISEASE: A PRELIMINARY STUDY.Acta endocrinologica (Bucharest, Romania : 2005)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Graves' disease (GD) is the most common cause of hyperthyroidism worldwide. Current therapeutic options for GD include antithyroid drugs (ATD), radioactive iodine, and thyroidectomy. ATD treatment is generally well accepted by patients and clinicians due to some advantages including normalizing thyroid function in a short time, hardly causing hypothyroidism, and ameliorating immune disorder while avoiding radiation exposure and invasive procedures. However, the relatively high recurrence rate is a major concern for ATD treatment, which is associated with multiple influencing factors like clinical characteristics, treatment strategies, and genetic and environmental factors. Of these influencing factors, some are modifiable but some are nonmodifiable. The recurrence risk can be reduced by adjusting the modifiable factors as much as possible. The titration regimen for 12-18 months is the optimal strategy of ATD. Levothyroxine administration after successful ATD treatment was not recommended. The addition of immunosuppressive drugs might be helpful to decrease the recurrence rate of GD patients after ATD withdrawal, whereas further studies are needed to address the safety and efficacy. This paper reviewed the current knowledge of ATD treatment and mainly focused on influencing factors for recurrence in GD patients with ATD treatment.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.